Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SeaStar Medical Holding Corporation filings document a medical-device issuer with common stock and publicly listed warrants, registration activity, governance matters, and material events. Securities Act registration statements describe delayed or continuous securities offerings and related capital-structure disclosures, while proxy materials cover annual-meeting voting procedures, board and governance matters, and compensation disclosures.
Current reports on Form 8-K record operating results, QUELIMMUNE and SCD business updates furnished with earnings releases, Nasdaq listing-compliance matters, officer appointments and compensation arrangements, and completed litigation-status disclosures. The filings also frame disclosure topics tied to QUELIMMUNE commercialization, SCD clinical development, FDA post-approval obligations, risk factors, and financing activity.
SeaStar Medical Holding Corporation (ICU) called a special stockholder meeting for December 18, 2025 at 10 am MST (virtual) to vote on capital structure changes. The Board seeks approval to effect a 1-for-10 reverse stock split of common stock at the Board’s discretion within one year, with fractional shares rounded up to the nearest whole share and no change to par value.
The Board also proposes reducing authorized common shares by 25,000,000 to 425,000,000, and an adjournment option if more time is needed to secure votes. The company cites Nasdaq’s $1.00 minimum bid requirement and potential delisting risk as key reasons to pursue the reverse split, noting the common stock closed at $0.5506 on November 3, 2025. Holders of record on November 3, 2025 may vote; 35,865,834 shares were outstanding as of that date. The Board recommends voting FOR all proposals.
SeaStar Medical Holding Corp. (ICU) reported Q3 2025 results showing early commercial traction and a strengthened balance sheet, alongside continued operating losses. Net revenue was $183 thousand for the quarter and $814 thousand for the first nine months, reflecting initial sales of QUELIMMUNE, the FDA-approved pediatric SCD therapy. Q3 net loss was $3.5 million, improving from $4.5 million a year ago, as operating expenses declined.
Cash rose to $13.8 million as of September 30, 2025, up from $1.8 million at year-end, driven by equity financings and warrant exercises. Stockholders’ equity improved to $11.5 million from a deficit at December 31, 2024, with 34.1 million shares outstanding at quarter-end and 36.0 million as of November 7, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting that additional capital is needed to fund operations and clinical programs. Subsequent to quarter-end, the company raised $1.2 million gross via its ATM and financed its D&O insurance with a short-term note.
SeaStar Medical Holding Corporation filed an 8-K stating it has furnished a press release with results for the three and nine months ended September 30, 2025, as Exhibit 99.1 under Item 2.02.
The information is furnished, not filed, under the Exchange Act, is not subject to Section 18 liabilities, and is not incorporated by reference. The company’s securities trade on Nasdaq as ICU (common) and ICUCW (warrants).
SeaStar Medical Holding Corporation called a virtual special meeting to seek stockholder approval for three items: a 1‑for‑10 reverse stock split, a reduction of authorized common shares by 25,000,000 to 425,000,000, and the ability to adjourn the meeting if needed. The meeting is set for December 18, 2025 at 10 am MST.
Under the reverse split, the Board may implement the action in its sole discretion within one year after the meeting; authorized share counts would not change under this item, and fractional shares would be rounded up to the nearest whole share. Proposal 2 would amend the charter to decrease authorized common shares to 425,000,000. The Board recommends voting FOR all proposals.
The company notes the reverse split is intended to help address Nasdaq’s minimum bid price requirement of $1.00 and preserve listing. Holders of record on November 3, 2025 may vote; shares outstanding were 35,865,834 as of that date. Each proposal passes with a majority of votes cast; abstentions and broker non‑votes have no effect.
SeaStar Medical Holding Corporation launched an at‑the‑market offering of up to $2,279,989 of common stock under its S‑3 shelf, with H.C. Wainwright as sales agent. Sales may be made on Nasdaq or otherwise at prevailing prices. Wainwright will receive a 3.0% cash commission on gross sales, and will be deemed an underwriter for these transactions.
The company intends to use net proceeds for general corporate purposes. As of October 10, 2025, ICU last traded at $0.5716 and its listed warrants at $0.0301. SeaStar notes its public float was $42,019,639 (33,886,805 non‑affiliate shares at $1.24) and that it remains subject to Form S‑3 I.B.6 limits; it sold $11,726,556 over the prior 12 months. Nasdaq has notified the company of $1.00 minimum bid non‑compliance; SeaStar has until January 27, 2026 to regain compliance. If all ATM shares were sold at $0.5716, common stock outstanding would rise to up to 38,085,204 shares; the actual number depends on sale prices.
SeaStar Medical Holding Corporation reported that its Board of Directors approved increases to the annual base salaries of Chief Executive Officer Eric Schlorff, Chief Medical Officer Kevin Chung, and certain other members of management, effective October 1, 2025. Their salaries had been set at 2024 levels and then reduced by 20% in June 2025 as part of efforts to lower monthly operating expenses.
The Board also approved restoring each director’s cash retainer fees, and any additional cash retainer fees, back to original levels as of October 1, 2025, after these had likewise been reduced by 20% in June 2025. As a result of these compensation changes and other actions, the company expects monthly operating expenses to increase by approximately $50,000.
SeaStar Medical Holding Corporation reported that an independent Data Safety Monitoring Review Board recommended continuing its NEUTRALIZE-AKI pivotal trial of the Selective Cytopheretic Device in adults with acute kidney injury requiring continuous renal replacement therapy. The board cited zero device-related safety issues and advised increasing total trial enrollment to 339 patients to meet the original statistical powering assumptions.
SeaStar Medical Holding Corp (ICU) Form 3 filed by Bradford K. Towne reports beneficial ownership of 15,500 shares of common stock. The filing is an initial statement under Section 16 and reflects stock awards rather than open-market purchases.
The 15,500 shares include 5,000 restricted stock units (RSUs) from an April 12, 2024 grant of 8,000 RSUs that vest monthly through February 2028 and 7,500 RSUs granted April 1, 2025 that vest in three equal tranches on April 1, 2026, 2027 and 2028. Towne is identified as the issuer's Principal Accounting Officer. The event date triggering the report is 08/26/2025 and the form is signed on 09/09/2025.
SeaStar Medical Holding Corp (ICU) director Kenneth Van Heel reported open-market purchases totaling 35,000 shares across two days. On 08/26/2025 he acquired 25,000 shares at a weighted-average price of $0.8899, increasing his direct holdings to 39,400 shares. On 08/27/2025 he acquired 10,000 shares at a weighted-average price of $0.8565, raising his direct holdings to 49,400 shares.
The Form 4 shows these were non-derivative purchases and that no derivative securities were reported. The filing was submitted by an attorney-in-fact on 08/28/2025.
SeaStar Medical insider purchase: Chief Medical Officer Kevin Chung purchased 10,000 shares of SeaStar Medical Holding Corp (ICU) on 08/22/2025 at a reported price of $0.80 per share, increasing his beneficial ownership to 58,184 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or additional remarks were reported.